- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Viracta Therapeutics Inc (VIRX)
Viracta Therapeutics Inc stock price live, this page displays OTC VIRX stock exchange data. View the VIRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Viracta Therapeutics Inc real time stock price chart below.
What Is the Viracta Therapeutics Inc Stock Price Today?
The Viracta Therapeutics Inc stock price today is 0.0170.
What Is the Stock Symbol for Viracta Therapeutics Inc?
The stock ticker symbol for Viracta Therapeutics Inc is VIRX.
Is VIRX the Same as $VIRX?
$VIRX is a common way to refer to the Viracta Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Viracta Therapeutics Inc Trade On?
Viracta Therapeutics Inc is listed and trades on the OTC Markets stock exchange.
Is Viracta Therapeutics Inc a Good Stock to Buy?
Determining whether Viracta Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Viracta Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VIRX quote. (ISIN: US92765F1084)
What Is the Viracta Therapeutics Inc Stock Price Today?
The Viracta Therapeutics Inc stock price today is 0.0170.
What Is the Stock Symbol for Viracta Therapeutics Inc?
The stock ticker symbol for Viracta Therapeutics Inc is VIRX.
Is VIRX the Same as $VIRX?
$VIRX is a common way to refer to the Viracta Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Viracta Therapeutics Inc Trade On?
Viracta Therapeutics Inc is listed and trades on the OTC Markets stock exchange.
Is Viracta Therapeutics Inc a Good Stock to Buy?
Determining whether Viracta Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Viracta Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VIRX quote. (ISIN: US92765F1084)
OTC Markets
Currency in USD
0.0170
-0.0005(-2.86%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0170
0.0173
52 wk Range
0.0080
0.8700
VIRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
More Info
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.01700.0173
52 wk Range
0.00800.8700
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VIRX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Viracta Therapeutics strikes deal to avoid default
- Investing.com
- VIRX stock plunges to 52-week low, touches $0.08
- Investing.com
- Viracta Therapeutics to be delisted from Nasdaq
- Investing.com
Viracta Therapeutics Inc Company Profile
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Viracta Therapeutics Inc SWOT Analysis
Financial Challenges | With a $4 price target from RBC Capital Markets, Viracta faces cash burn concerns while streamlining operations to extend runway |
Market Niche Strategy | Explore Viracta's concentrated efforts in EBV+ lymphomas, balancing specialized expertise against a narrower addressable market |
Regulatory Clarity | FDA discussions yield potential accelerated approval path for Nana-val, with filing targeted for 2026 based on NAVAL-1 study results |
Pipeline Pivot | Viracta Therapeutics narrows focus to Nana-val for EBV+ peripheral T-cell lymphoma, pausing solid tumor program for streamlined development |
Compare VIRX to Peers and Sector
Metrics to compare | VIRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −3.4x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price / Book | −0.1x | 1.8x | 2.6x | |
Price / LTM Sales | - | 16.9x | 2.9x | |
Upside (Analyst Target) | - | 228.6% | 45.8% | |
Fair Value Upside | Unlock | 5.3% | 8.6% | Unlock |
Earnings
Latest Release
Mar 31, 2025
EPS / Forecast
-0.27 / -0.1933
Revenue / Forecast
-- / --
FAQ
What Is the Viracta Therapeutics (VIRX) Stock Price Today?
The Viracta Therapeutics stock price today is 0.02
What Stock Exchange Does Viracta Therapeutics Trade On?
Viracta Therapeutics is listed and trades on the OTC Markets stock exchange.
What Is the Stock Symbol for Viracta Therapeutics?
The stock symbol for Viracta Therapeutics is "VIRX."
What Is the Viracta Therapeutics Market Cap?
As of today, Viracta Therapeutics market cap is 675.65K.
What Is Viracta Therapeutics's Earnings Per Share (TTM)?
The Viracta Therapeutics EPS (TTM) is -1.10.
When Is the Next Viracta Therapeutics Earnings Date?
Viracta Therapeutics will release its next earnings report on May 16, 2025.
From a Technical Analysis Perspective, Is VIRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.